# Denali Therapeutics Inc.: overview

DNLI · Nasdaq · CIK 1714899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dnli.md) · [Financials](/companies/dnli/financials.md) · [Filings](/companies/dnli/filings.md) · [Insiders](/companies/dnli/insiders.md)

Latest reported revenue: [$3.6m](/filings/0001714899-26-000097.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001714899-26-000097).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001714899-24-000216.md) | [0.0 d](/filings/0001714899-26-000021.md) | not reported | [0.0](/filings/0001714899-26-000097.md) | not reported | not reported | not reported | [3.6](/filings/0001714899-26-000097.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(3622.1%)](/filings/0001714899-26-000097.md) |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(3539.2%)](/filings/0001714899-26-000097.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0001714899-25-000193.md) | not reported | [(0.78)](/filings/0001714899-26-000064.md) | [(0.72)](/filings/0001714899-26-000097.md) | [(0.74)](/filings/0001714899-25-000193.md) | not reported | [(0.69)](/filings/0001714899-26-000064.md) | [(0.68)](/filings/0001714899-26-000097.md) |
| Free cash flow | $m | [(63.0) d](/filings/0001714899-25-000193.md) | [(88.8) d](/filings/0001714899-26-000021.md) | [(137)](/filings/0001714899-26-000064.md) | [(79.6) d](/filings/0001714899-26-000097.md) | [(109) d](/filings/0001714899-25-000193.md) | [(100) d](/filings/0001714899-26-000021.md) | [(134)](/filings/0001714899-26-000064.md) | [(97.8) d](/filings/0001714899-26-000097.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [48.7](/filings/0001714899-24-000086.md) | [105](/filings/0001714899-25-000066.md) | [331](/filings/0001714899-26-000021.md) | [0.0](/filings/0001714899-26-000021.md) | [0.0](/filings/0001714899-26-000021.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(607.8%)](/filings/0001714899-24-000086.md) | [(324.3%)](/filings/0001714899-25-000066.md) | [(59.5%)](/filings/0001714899-26-000021.md) | not reported | not reported |
| Net margin | % | [(597.2%)](/filings/0001714899-24-000086.md) | [(310.3%)](/filings/0001714899-25-000066.md) | [(43.9%)](/filings/0001714899-26-000021.md) | not reported | not reported |
| Diluted EPS | $ per share | [(2.39)](/filings/0001714899-24-000086.md) | [(2.60)](/filings/0001714899-25-000066.md) | [(1.06)](/filings/0001714899-26-000021.md) | [(2.57)](/filings/0001714899-26-000021.md) | [(2.97)](/filings/0001714899-26-000021.md) |
| Free cash flow | $m | [(220)](/filings/0001714899-24-000086.md) | [(263)](/filings/0001714899-25-000066.md) | [(371)](/filings/0001714899-26-000021.md) | [(364)](/filings/0001714899-26-000021.md) | [(422)](/filings/0001714899-26-000021.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dnli/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $360.8m | 14,026,413 |  | Added +991,979 |
| [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $307.6m | 11,960,230 |  | Reduced −106,249 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $181.3m | 7,049,304 |  | Added +777,303 |
| [Temasek Holdings (Private) Ltd](/funds/1021944.md) | 2026-06-30 | $180.4m | 7,012,974 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $166.6m | 6,477,057 |  | Added +356,897 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $161.4m | 6,275,729 |  | Added +127,772 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $116.7m | 4,535,836 |  | Reduced −39,538 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $106.9m | 4,155,895 |  | Reduced −251,360 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $102.2m | 3,973,342 |  | Added +246,228 |
| [Holocene Advisors, LP](/funds/1700574.md) | 2026-06-30 | $100.4m | 3,905,225 |  | Added +709,796 |

## Recent filings

[All 780 filings](/companies/dnli/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:08 ET | [10-Q](/filings/0001714899-26-000097.md) | Quarterly report, period 2026-06-30 | 0001714899-26-000097 |
| 2026-08-06 | 16:03 ET | [8-K](/filings/0001714899-26-000096.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000096 |
| 2026-07-28 | 21:01 ET | [8-K](/filings/0001714899-26-000086.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001714899-26-000086 |
| 2026-06-18 | 08:01 ET | [8-K](/filings/0001714899-26-000081.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000081 |
| 2026-06-04 | 18:43 ET | [8-K](/filings/0001714899-26-000074.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-26-000074 |
| 2026-05-22 | 18:17 ET | [8-K](/filings/0001714899-26-000070.md) | 7.01 Regulation FD disclosure | 0001714899-26-000070 |
| 2026-05-07 | 16:12 ET | [10-Q](/filings/0001714899-26-000064.md) | Quarterly report, period 2026-03-31 | 0001714899-26-000064 |
| 2026-05-07 | 16:03 ET | [8-K](/filings/0001714899-26-000062.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000062 |
| 2026-04-21 | 16:31 ET | [DEF 14A](/filings/0001714899-26-000054.md) | Proxy statement, period 2025-12-31 | 0001714899-26-000054 |
| 2026-04-03 | 14:43 ET | [8-K](/filings/0001714899-26-000042.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001714899-26-000042 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001714899-26-000021.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/62e4c3cc-c331-43ea-8388-2be87b90fa00)

## About the filer

- CIK: 1714899
- Tickers: DNLI
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.